These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 973254)

  • 1. [A case of mental change resulting from L-dopa treatment].
    Gulmann NC
    Ugeskr Laeger; 1976 Oct; 138(41):2497-8. PubMed ID: 973254
    [No Abstract]   [Full Text] [Related]  

  • 2. [L-dopa-induced psychoses and their treatment with L-tryptophan].
    Demling J
    Fortschr Med; 1986 Apr; 104(17):360-2. PubMed ID: 3710403
    [No Abstract]   [Full Text] [Related]  

  • 3. [L-dopa-decarboxylase inhibitor combination preparation (Sinemet) in parkinsonism and syndromes imitating parkinsonism. 1 year's experience with 34 patients].
    Holmsen R
    Tidsskr Nor Laegeforen; 1976 Feb; 96(4):225, 234-6. PubMed ID: 1251394
    [No Abstract]   [Full Text] [Related]  

  • 4. Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug-induced psychosis.
    Arnold G; Trenkwalder C; Schwarz J; Oertel WH
    Mov Disord; 1994 Mar; 9(2):238-40. PubMed ID: 7910949
    [No Abstract]   [Full Text] [Related]  

  • 5. [Acute psychotic status after sudden interruption of treatment of Parkinsonism with levodopa].
    Ledić P; Sepcić J; Antoncić N
    Neurologija; 1977; 25(1-2):95-7. PubMed ID: 616879
    [No Abstract]   [Full Text] [Related]  

  • 6. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy.
    Melamed E; Zoldan J; Friedberg G; Ziv I; Weizmann A
    Adv Neurol; 1996; 69():545-50. PubMed ID: 8615179
    [No Abstract]   [Full Text] [Related]  

  • 7. Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease.
    Duggal HS; Singh I
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):583-4. PubMed ID: 18022304
    [No Abstract]   [Full Text] [Related]  

  • 8. Exogenous levodopa is not toxic to elderly subjects with non-parkinsonian movement disorders: further clinical evidence.
    Hagenah J; Klein C; Sieberer M; Vieregge P
    J Neural Transm (Vienna); 1999; 106(3-4):301-7. PubMed ID: 10392538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zotepine in levodopa-induced Psychosis.
    Spieker S; Stetter F; Klockgether T
    Mov Disord; 1995 Nov; 10(6):795-7. PubMed ID: 8750001
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clozapine, a valuable contribution for the treatment of psychoses in Parkinson disease].
    Andersson U; Freccero-Rosman K; Aquilonius SM; Nylander B; Lindvall O; Odin P
    Lakartidningen; 1992 Dec; 89(49):4244-6. PubMed ID: 1461047
    [No Abstract]   [Full Text] [Related]  

  • 12. Parkinson disease. Individualizing therapy.
    Feldman RG; Lannon MC
    Hosp Pract (Off Ed); 1985 Jan; 20(1):80A-80E, 80I, 80M, passim. PubMed ID: 3917453
    [No Abstract]   [Full Text] [Related]  

  • 13. [Acute psychoses and mood disorders in Parkinson disease. Role of antiparkinson therapy].
    Mouren P; Poinso Y; Oppenheim G; Mouren A; Nguyen Quang N
    Ann Med Psychol (Paris); 1983; 141(8):843-57. PubMed ID: 6666915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Levodopa dependency in Parkinson's disease: case report and review].
    Müller U; Reuter M; Hermann W; Gertz HJ
    Nervenarzt; 2002 Sep; 73(9):887-91. PubMed ID: 12215883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
    Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
    J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 18. [Reports on mental disorders in Parkinson disease in relation to treatment with L-dopa].
    Agostino R; Fabri S
    Riv Neurobiol; 1983; 29(4):577-84. PubMed ID: 6678478
    [No Abstract]   [Full Text] [Related]  

  • 19. [The deterioration of patients with parkinsonism treated with L-dopa].
    Guillard A
    Nouv Presse Med; 1975 Oct; 4(35):2503-6. PubMed ID: 1196872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy of tparkinson's disease. Clinical and pharmacological viewpoints].
    Przuntek H
    Med Klin; 1979 Jul; 74(28-29):1077-83. PubMed ID: 39230
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.